NiKang Therapeutics has initiated a global Phase 1b/2 clinical trial evaluating NKT2152, an oral HIF2α inhibitor, in combination with atezolizumab and bevacizumab for first-line treatment of advanced or metastatic hepatocellular carcinoma (HCC). This trial, part of Roche’s MORPHEUS-liver platform, will compare the combination therapy to the standard atezolizumab and bevacizumab regimen. Preclinical data suggests NKT2152 has broad anti-tumor activity, making HCC a promising target beyond its current trials in renal cell carcinoma.
This trial is significant because it expands the potential applications of NKT2152 into a new and prevalent cancer type. HCC has limited treatment options, and the existing standard-of-care therapy, while effective, may not be sufficient for all patients. A successful trial could offer a new combination treatment approach with improved efficacy, potentially benefiting a significant number of patients. Furthermore, the collaboration with Roche and inclusion within the MORPHEUS platform provides external validation of NKT2152’s potential and offers access to Roche’s extensive clinical development expertise.
This Phase 1b/2 trial combines NKT2152 with the established HCC standard-of-care regimen. NKT2152 inhibits HIF2α, a protein implicated in tumor growth. The drug’s pharmacokinetic profile, characterized by high systemic exposure and long half-life, makes it suitable for combination with antibody-based therapies. NKT2152 is also being evaluated in other clinical trials, including studies for renal cell carcinoma as a single agent and in combination with other drugs.
The initiation of this HCC trial marks a crucial step in expanding the clinical evaluation of NKT2152. Positive results could lead to a new treatment option for HCC, addressing an unmet medical need. It also positions NiKang as a key player in developing innovative cancer therapies and strengthens their ongoing collaboration with Roche. The data from this trial will be critical for determining the future development and potential regulatory pathways for NKT2152 in HCC.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
